PDCD1 and non-small cell lung carcinoma: In the PERLA study, the addition of dostarlimab, a humanized anti–PD-1 mAb, that binds the PD-1 receptor in platinum-based chemotherapy in previously untreated patients with advanced non–squamous NSCLC without known targetable genomic aberrations demonstrated comparable survival outcomes in patients who received pembrolizumab and platinum-based chemotherapy (20), supporting further investigation of dostarlimab in combination with other treatments in NSCLC.